Global Cancer Monoclonal Antibodies Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Veröffentlicht von: precision business insights
Veröffentlicht am: 02.02.2018 07:52
Rubrik: Gesundheit & Medizin

(Presseportal openBroadcast) - Global Cancer Monoclonal Antibodies Market

A monoclonal antibody drug in cancer treatments engages natural immune system functions to fight cancer. Cancer monoclonal antibodies may be used in combination with other cancer treatments. An antibody attaches itself to a specific molecule (antigen) on the surface of cancer cell when antibody binds to antigen, it acts as a flag to attract disease-fighting molecules or as a trigger that promotes the destruction of cancer cells by another immune system process. Due to its specificity, monoclonal antibodies have least adverse effects than other cancer treating drugs.

The market growth of cancer monoclonal antibodies is driven by increased prevalence of cancer worldwide. According to WHO, cancer is one of the leading cause of deaths worldwide. In 2012, there were around 14 Mn new cases of cancer, 8.2 Mn people died because of cancer and numbers of new cancer cases are projected to rise 70% in coming decades. In addition, monoclonal antibodies are proved to be having less adverse effects when compared to conventional non-targeted therapies. Increasing investment in the development of monoclonal antibodies, technological advancements that enabling the genetic sequencing and increasing specificity of the antibodies are fueling the sales revenue of cancer monoclonal antibodies market. However, the high cost of development, stringent regulatory guidelines, long period of clinical trials, are some of the factors hinder growth of cancer monoclonal antibodies market. Monoclonal antibodies are very specific in nature and have limited targets.

A sample of this report is available upon request @

Cancer monoclonal antibodies market has been segmented based on application, type and conjugation, and distribution channel

Base on application, cancer monoclonal antibodies market is segmented into
• Breast Cancer
• Blood Cancer
• Liver Cancer
• Brain cancer
• Colorectal Cancer
• Others

Based on type of antibody, cancer monoclonal antibodies market is segmented into
• Murine Antibodies
• Humanized Antibodies
• Chimeric Antibodies

Based on conjugation, cancer monoclonal antibodies market is segmented into
• Immunocytokines
• Immunoliposome
• Radioimmunotherapy
• Antibody Directed Enzyme Prodrug Therapy(ADEPT)

Based on distribution channel, cancer monoclonal antibodies market segmented into
• Hospital Pharmacies
• Retail Pharmacies
• Clinics

To view TOC of this report is available upon request @
Currently cancer monoclonal antibodies market is witnessing a significant growth. The targeted and combination therapy drugs are leading in the market. Several market player collaborating to develop antibody drugs to treat various type of cancers. In January 2017, AbCellera Biologics, Inc. collaborated with Pfizer Inc. for new therapeutic antibody discovery. AbCellera will use its monoclonal antibody (mAb) screening techniques in the discovery of function modulating antibodies against undisclosed membrane protein targets. Academic institutions and organisations like National Institute of Health (USA), National Cancer Institute (USA) and many others are collaborating and participating in cancer research and awareness activities.

Need more information about this report @

Geographically cancer monoclonal antibodies market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America cancer monoclonal antibodies market is growing at a steady rate due to increased prevalence of various cancers and higher acceptance of existing monoclonal antibodies among healthcare professionals in the region. According to National Cancer Institute (NIH), an estimated 1,685,210 new cases of cancer were diagnosed in the United States and 595,690 people will die from the disease in 2016. Asia-Pacific region is expected to exhibit rapid growth due to rise in government spending on healthcare infrastructure, increasing R&D spending by companies and growing patient and healthcare professional awareness in therapeutic use of monoclonal antibodies in treatment of cancer. For instance, Government-led fund providers, such as National Natural Science Foundation and National Basic Research Program of China, offer financial support to enterprises and universities to conduct monoclonal antibody research and development. The presence of healthcare regulations and procedures to promote early treatment of diseases using advanced therapeutics and public policies to support early screening and effective treatments for various cancers is driving the cancer monoclonal antibodies market in Latin-America.

Some of the players in cancer monoclonal antibodies market are Merck & Co. Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Spectrum Pharmaceuticals (U.S.), Eli Lilly and Company (U.S.), Amgen Inc. (U.S.), Bristol-Meyer Squibb (U.S.), Sanofi (France) and AstraZeneca (U.K.) to name a few.
Get access to full summary @

About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Precision Business Insights mission is to provide high-quality market research reports and generate key insights to our clients. PBI’s approachable strategies are to help clients to make key decisions for business growth.Precision Business Insights vision is to become most valued partner to fortune 500 companies by providing agile, accurate, and actionable market insights
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Toll Free (US): +1-866-598-1553
Website @


Kemp House,
152 – 160 City Road,
London EC1V 2NX
Toll Free (US): +1-866-598-1553
Website @

Bitte beachten Sie, dass für den Inhalt der hier veröffentlichten Meldung nicht openBroadcast verantwortlich ist, sondern der Verfasser der jeweiligen Meldung selbst. AGB | Haftungsausschluss.